Status of vaccine research and development for Shigella

Vaccine

Volumn 34, Issue 26, 2016, Pages 2887-2894

  Mani, Sachin ^a   Wierzba, Thomas ^a   Walker, Richard I ^a  

^a PATH   (United States)

Author keywords

Adjuvants; Combined vaccines; Diarrheal disease; Enteric vaccines; Impact assessment; Shigella

Indexed keywords

ANTIGEN; GLYCOCONJUGATE; SHIGELLA VACCINE; SUBUNIT VACCINE; VACCINE;

ARTICLE; DRUG RESEARCH; HUMAN; INCIDENCE; NONHUMAN; OBSERVATIONAL STUDY; PRIORITY JOURNAL; SHIGELLA; SHIGELLOSIS; ANIMAL; CLINICAL TRIAL (TOPIC); DIARRHEA; DISEASE MODEL; DYSENTERY, BACILLARY; MEDICAL RESEARCH; MICROBIOLOGY; TRENDS;

ANIMALS; BIOMEDICAL RESEARCH; CLINICAL TRIALS AS TOPIC; DIARRHEA; DISEASE MODELS, ANIMAL; DYSENTERY, BACILLARY; HUMANS; SHIGELLA; SHIGELLA VACCINES; VACCINES, CONJUGATE; VACCINES, SUBUNIT;

EID: 84962164822     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2016.02.075     Document Type: Article

References (77)

1. Kotloff K.L., Winickoff J.P., Ivanoff B., Clemens J.D., Swerdlow D.L., Sansonetti P.J., et al. Global burden of Shigella infections: implications for vaccine development and implementation of control strategies. Bull World Health Organ 1999, 77:651-666.
2. Kotloff K.L., Nataro J.P., Blackwelder W.C., Nasrin D., Farag T.H., Panchalingam S., et al. Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study. Lancet 2013, 382:209-222.
3. Platts-Mills J.A., Babji S., Bodhidatta L., Gratz J., Haque R., Havt A., et al. Pathogen-specific burdens of community diarrhoea in developing countries: a multisite birth cohort study (MAL-ED). Lancet Glob Health 2015, 3:e564-e575.
4. Lanata C.F., Fischer-Walker C.L., Olascoaga A.C., Torres C.X., Aryee M.J., Black R.E., et al. Global causes of diarrheal disease mortality in children <5 years of age: a systematic review. PLOS ONE 2013, 8:e72788.
5. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015, 386:743-800. Global Burden of Disease Study Collaborators.
6. Lamberti L.M., Bourgeois A.L., Fischer Walker C.L., Black R.E., Sack D. Estimating diarrheal illness and deaths attributable to Shigellae and enterotoxigenic Escherichia coli among older children, adolescents, and adults in South Asia and Africa. PLOS Negl Trop Dis 2014, 8:e2705.
7. GBD 2013 Mortality and Causes of Death Collaborators Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015, 385:117-171.
8. Murray C.J., Vos T., Lozano R., Naghavi M., Flaxman A.D., Michaud C., et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012, 380:2197-2223.
9. Vos T., Flaxman A.D., Naghavi M., Lozano R., Michaud C., Ezzati M., et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012, 380:2163-2196.
10. Lindsay B., Ochieng J.B., Ikumapayi U.N., Toure A., Ahmed D., Li S., et al. Quantitative PCR for detection of Shigella improves ascertainment of Shigella burden in children with moderate-to-severe diarrhea in low-income countries. J Clin Microbiol 2013, 51:1740-1746.
11. Schmid-Hempel P., Frank S.A. Pathogenesis, virulence, and infective dose. PLoS Pathog 2007, 3:1372-1373.
12. Das S.K., Ahmed S., Ferdous F., Farzana F.D., Chisti M.J., Leung D.T., et al. Changing emergence of Shigella sero-groups in Bangladesh: observation from four different diarrheal disease hospitals. PLOS ONE 2013, 8:e62029.
13. Livio S., Strockbine N.A., Panchalingam S., Tennant S.M., Barry E.M., Marohn M.E., et al. Shigella isolates from the Global Enteric Multicenter Study Inform Vaccine Development. Clin Infect Dis 2014, 59:933-941.
14. Formal S.B., Oaks E.V., Olsen R.E., Wingfield-Eggleston M., Snoy P.J., Cogan J.P. Effect of prior infection with virulent Shigella flexneri 2a on the resistance of monkeys to subsequent infection with Shigella sonnei. J Infect Dis 1991, 164:533-537.
15. DuPont H.L., Hornick R.B., Snyder M.J., Libonati J.P., Formal S.B., Gangarosa E.J. Immunity in shigellosis. II. Protection induced by oral live vaccine or primary infection. J Infect Dis 1972, 125:12-16.
16. Kotloff K.L., Nataro J.P., Losonsky G.A., Wasserman S.S., Hale T.L., Taylor D.N., et al. A modified Shigella volunteer challenge model in which the inoculum is administered with bicarbonate buffer: clinical experience and implications for Shigella infectivity. Vaccine 1995, 13:1488-1494.
17. Abu-Elyazeed R.R., Wierzba T.F., Frenck R.W., Putnam S.D., Rao M.R., Savarino S.J., et al. Epidemiology of Shigella-associated diarrhea in rural Egyptian children. Am J Trop Med Hyg 2004, 71:367-372.
18. Ferreccio C., Prado V., Ojeda A., Cayyazo M., Abrego P., Guers L., et al. Epidemiologic patterns of acute diarrhea and endemic Shigella infections in children in a poor periurban setting in Santiago, Chile. Am J Epidemiol 1991, 134:614-627.
19. Cohen D., Green M.S., Block C., Rouach T., Ofek I. Serum antibodies to lipopolysaccharide and natural immunity to shigellosis in an Israeli military population. J Infect Dis 1988, 157:1068-1071.
20. Cohen D., Green M.S., Block C., Slepon R., Ofek I. Prospective study of the association between serum antibodies to lipopolysaccharide O antigen and the attack rate of shigellosis. J Clin Microbiol 1991, 29:386-389.
21. Levine M.M., Kotloff K.L., Barry E.M., Pasetti M.F., Sztein M.B. Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road. Nat Rev Microbiol 2007, 5:540-553.
22. Simon J.K., Maciel M., Weld E.D., Wahid R., Pasetti M.F., Picking W.L., et al. Antigen-specific IgA B memory cell responses to Shigella antigens elicited in volunteers immunized with live attenuated Shigella flexneri 2a oral vaccine candidates. Clin Immunol 2011, 139:185-192.
23. Camacho A.I., Irache J.M., Gamazo C. Recent progress towards development of a Shigella vaccine. Expert Rev Vaccines 2013, 12:43-55.
24. Kaminski R.W., Oaks E.V. Inactivated and subunit vaccines to prevent shigellosis. Expert Rev Vaccines 2009, 8:1693-1704.
25. Venkatesan M.M., Ranallo R.T. Live-attenuated Shigella vaccines. Expert Rev Vaccines 2006, 5:669-686.
26. Walker R.I. An assessment of enterotoxigenic Escherichia coli and Shigella vaccine candidates for infants and children. Vaccine 2015, 33:954-965.
27. Schroeder G.N., Hilbi H. Molecular pathogenesis of Shigella spp.: controlling host cell signaling, invasion, and death by type III secretion. Clin Microbiol Rev 2008, 21:134-156.
28. Ashida H., Mimuro H., Sasakawa C. Shigella manipulates host immune responses by delivering effector proteins with specific roles. Front Immunol 2015, 6:219.
29. Phalipon A., Sansonetti P.J. Shigella's ways of manipulating the host intestinal innate and adaptive immune system: a tool box for survival. Immunol Cell Biol 2007, 85:119-129.
30. Barry E.M., Pasetti M.F., Sztein M.B., Fasano A., Kotloff K.L., Levine M.M. Progress and pitfalls in Shigella vaccine research. Nat Rev Gastroenterol Hepatol 2013, 10:245-255.
31. Simon J.K., Maciel M., Weld E.D., Wahid R., Pasetti M.F., Picking W.L., et al. Antigen-specific IgA B memory cell responses to Shigella antigens elicited in volunteers immunized with live attenuated Shigella flexneri 2a oral vaccine candidates. Clin Immunol (Orlando, Fla) 2011, 139:185-192.
32. Samandari T., Kotloff K.L., Losonsky G.A., Picking W.D., Sansonetti P.J., Levine M.M., et al. Production of IFN-γ and IL-10 to Shigella invasins by mononuclear cells from volunteers orally inoculated with a Shiga toxin-deleted Shigella dysenteriae Type 1 strain. J Immunol 2000, 164:2221-2232.
33. Boyd M.A., Tennant S.M., Saague V.A., Simon R., Muhsen K., Ramachandran G., et al. Serum bactericidal assays to evaluate typhoidal and nontyphoidal Salmonella vaccines. Clin Vaccine Immunol 2014, 21:712-721.
34. Burton R.L., Nahm M.H. Development and validation of a fourfold multiplexed opsonization assay (MOPA4) for pneumococcal antibodies. Clin Vaccine Immunol 2006, 13:1004-1009.
35. Shimanovich A.A.B., Amanda D., Franco-Mahecha O.L., Heine S.J., Mayo I., Blackwelder W.C., et al. Functional antibodies against Shigella and their association with protection against disease in humans 2015, Vaccines for Enteric Diseases Edinburgh, Scotland.
36. Hartman A.B., Powell C.J., Schultz C.L., Oaks E.V., Eckels K.H. Small-animal model to measure efficacy and immunogenicity of Shigella vaccine strains. Infect Immun 1991, 59:4075-4083.
37. Hartman A.B., Van de Verg L.L., Collins H.H., Tang D.B., Bendiuk N.O., Taylor D.N., et al. Local immune response and protection in the guinea pig keratoconjunctivitis model following immunization with Shigella vaccines. Infect Immun 1994, 62:412-420.
38. Sereny B. Experimental Shigella keratoconjunctivitis; a preliminary report. Acta Microbiol Acad Sci Hung 1955, 2:293-296.
39. Mallett C.P., VanDeVerg L., Collins H.H., Hale T.L. Evaluation of Shigella vaccine safety and efficacy in an intranasally challenged mouse model. Vaccine 1993, 11:190-196.
40. Shipley S.T., Panda A., Khan A.Q., Kriel E.H., Maciel M., Livio S., et al. A challenge model for Shigella dysenteriae 1 in cynomolgus monkeys (Macaca fascicularis). Comp Med 2010, 60:54-61.
41. Jeong K.I., Zhang Q., Nunnari J., Tzipori S. A piglet model of acute gastroenteritis induced by Shigella dysenteriae Type 1. J Infect Dis 2010, 201:903-911.
42. Shim D.H., Suzuki T., Chang S.Y., Park S.M., Sansonetti P.J., Sasakawa C., et al. New animal model of shigellosis in the Guinea pig: its usefulness for protective efficacy studies. J Immunol 2007, 178:2476-2482.
43. Bodhidatta L., Pitisuttithum P., Chamnanchanant S., Chang K.T., Islam D., Bussaratid V., et al. Establishment of a Shigella sonnei human challenge model in Thailand. Vaccine 2012, 30:7040-7045.
44. Porter C.K., Thura N., Ranallo R.T., Riddle M.S. The Shigella human challenge model. Epidemiol Infect 2013, 141:223-232.
45. Ruuska T., Vesikari T. Rotavirus disease in Finnish children: use of numerical scores for clinical severity of diarrhoeal episodes. Scand J Infect Dis 1990, 22:259-267.
46. Gaston J.S., Inman R.D., Ryan E.T., Venkatesan M.M., Barry E.M., Hale T.L., et al. Vaccination of children in low-resource countries against Shigella is unlikely to present an undue risk of reactive arthritis. Vaccine 2009, 27:5432-5434.
47. Azizi A., Kumar A., Diaz-Mitoma F., Mestecky J. Enhancing oral vaccine potency by targeting intestinal M cells. PLoS Pathog 2010, 6:e1001147.
48. Luongo D., D'Arienzo R., Bergamo P., Maurano F., Rossi M. Immunomodulation of gut-associated lymphoid tissue: current perspectives. Int Rev Immunol 2009, 28:446-464.
49. Pizza M., Giuliani M.M., Fontana M.R., Monaci E., Douce G., Dougan G., et al. Mucosal vaccines: nontoxic derivatives of LT and CT as mucosal adjuvants. Vaccine 2001, 19:2534-2541.
50. Clements JD. Double mutant enterotoxin for use as an adjuvant. Google Patents (1999).
51. El-Kamary S.S., Cohen M.B., Bourgeois A.L., Van De Verg L., Bauers N., Reymann M., et al. Safety and immunogenicity of a single oral dose of recombinant double mutant heat-labile toxin derived from enterotoxigenic Escherichia coli. Clin Vaccine Immunol 2013, 20:1764-1770.
52. Norton E.B., Lawson L.B., Freytag L.C., Clements J.D. Characterization of a mutant Escherichia coli heat-labile toxin, LT(R192G/L211A), as a safe and effective oral adjuvant. Clin Vaccine Immunol 2011, 18:546-551.
53. Lawson L.B., Norton E.B., Clements J.D. Defending the mucosa: adjuvant and carrier formulations for mucosal immunity. Curr Opin Immunol 2011, 23:414-420.
54. Savelkoul H., Ferro V., Strioga M., Schijns V. Choice and design of adjuvants for parenteral and mucosal vaccines. Vaccines 2015, 3:148.
55. Orr N., Katz D.E., Atsmon J., Radu P., Yavzori M., Halperin T., et al. Community-based safety, immunogenicity, and transmissibility study of the Shigella sonnei WRSS1 vaccine in Israeli volunteers. Infect Immun 2005, 73:8027-8032.
56. Kotloff K.L., Simon J.K., Pasetti M., Sztein M.B., Wooden S.L., Livio S., et al. Safety and immunogenicity of CVD 1208S, a live, oral δguaBA δsen δset Shigella flexneri 2a vaccine grown on animal-free media. Hum Vaccines 2007, 3:268-275.
57. Ranallo R.T., Kaminski R.W., George T., Kordis A.A., Chen Q., Szabo K., et al. Virulence, inflammatory potential, and adaptive immunity induced by Shigella flexneri msbB mutants. Infect Immun 2010, 78:400-412.
58. Nagy G, Henics T, Szuarto V, Nagy E. A novel live attenuated shigella vaccine. Google Patents (2014).
59. Kim M.J.K.H., Rho S., Lee S.Y., Song M.K., Kim D.W., Czerkinsky C., et al. Development of a broad-spectrum vaccine against Shigellosis 2015, Vaccines for Enteric Diseases Edinburgh, Scotland.
60. Baron L.S., Kopecko D.J., Formal S.B., Seid R., Guerry P., Powell C. Introduction of Shigella flexneri 2a type and group antigen genes into oral typhoid vaccine strain Salmonella typhi Ty21a. Infect Immun 1987, 55:2797-2801.
61. Dharmasena M.N., Hanisch B.W., Wai T.T., Kopecko D.J. Stable expression of Shigella sonnei form I O-polysaccharide genes recombineered into the chromosome of live Salmonella oral vaccine vector Ty21a. Int J Med Microbiol 2013, 303:105-113.
62. Kaminski R.W., Wu M., Turbyfill K.R., Clarkson K., Tai B., Bourgeois A.L., et al. Development and preclinical evaluation of a trivalent, formalin-inactivated Shigella whole-cell vaccine. Clin Vaccine Immunol 2014, 21:366-382.
63. McKenzie R., Walker R.I., Nabors G.S., Verg L.L.V.D., Carpenter C., Gomes G., et al. Safety and immunogenicity of an oral, inactivated, whole-cell vaccine for Shigella sonnei: preclinical studies and a Phase I trial. Vaccine 2006, 24:3735-3745.
64. Szijarto V., Hunyadi-Gulyas E., Emody L., Pal T., Nagy G. Cross-protection provided by live Shigella mutants lacking major antigens. Int J Med Microbiol 2013, 303:167-175.
65. Passwell J.H., Harlev E., Ashkenazi S., Chu C., Miron D., Ramon R., et al. Safety and immunogenicity of improved Shigella O-specific polysaccharide-protein conjugate vaccines in adults in Israel. Infect Immun 2001, 69:1351-1357.
66. Passwell J.H., Ashkenzi S., Banet-Levi Y., Ramon-Saraf R., Farzam N., Lerner-Geva L., et al. Age-related efficacy of Shigella O-specific polysaccharide conjugates in 1-4-year-old Israeli children. Vaccine 2010, 28:2231-2235.
67. Bélot F., Guerreiro C., Baleux F., Mulard L.A. Synthesis of two linear PADRE conjugates bearing a deca- or pentadecasaccharide B epitope as potential synthetic vaccines against Shigella flexneri serotype 2a infection. Chemistry - Eur J 2005, 11:1625-1635.
68. Kämpf M.M., Braun M., Sirena D., Ihssen J., Thöny-Meyer L., Ren Q. In vivo production of a novel glycoconjugate vaccine against Shigella flexneri 2a in recombinant Escherichia coli: identification of stimulating factors for in vivo glycosylation. Microbial Cell Fact 2015, 14:12.
69. Braga C.J.M., Rodrigues J.F., Medina-Armenteros Y., Farinha-Arcieri L.E., Ventura A.M., Boscardin S.B., et al. Parenteral adjuvant effects of an enterotoxigenic Escherichia coli natural heat-labile toxin variant. Front Immunol 2013, 4:487.
70. Oaks EV, Turbyfill KR, Kaminski RW. Artificial invaplex. Google Patents (2014).
71. Rossi O., Pesce I., Giannelli C., Aprea S., Caboni M., Citiulo F., et al. Modulation of endotoxicity of Shigella generalized modules for membrane antigens (GMMA) by genetic lipid a modifications: relative activation of TLR4 and TLR2 pathways in different mutants. J Biol Chem 2014, 289:24922-24935.
72. Martinez-Becerra F.J., Kissmann J.M., Diaz-McNair J., Choudhari S.P., Quick A.M., Mellado-Sanchez G., et al. Broadly protective Shigella vaccine based on type III secretion apparatus proteins. Infect Immun 2012, 80:1222-1231.
73. Pore D., Chakrabarti M.K. Outer membrane protein A (OmpA) from Shigella flexneri 2a: a promising subunit vaccine candidate. Vaccine 2013, 31:3644-3650.
74. Szijártó V., Hunyadi-Gulyás É., Emody L., Pál T., Nagy G. Cross-protection provided by live Shigella mutants lacking major antigens. Int J Med Microbiol 2013, 303:167-175.
75. Pozsgay V., Chu C., Pannell L., Wolfe J., Robbins J.B., Schneerson R. Protein conjugates of synthetic saccharides elicit higher levels of serum IgG lipopolysaccharide antibodies in mice than do those of the O-specific polysaccharide from Shigella dysenteriae type 1. Proc Natl Acad Sci USA 1999, 96:5194-5197.
76. Turbyfill K.R., Kaminski R.W., Oaks E.V. Immunogenicity and efficacy of highly purified invasin complex vaccine from Shigella flexneri 2a. Vaccine 2008, 26:1353-1364.
77. Berlanda Scorza F., Colucci A.M., Maggiore L., Sanzone S., Rossi O., Ferlenghi I., et al. High yield production process for Shigella outer membrane particles. PLoS ONE 2012, 7:e35616.